Matthias Evert
Overview
Explore the profile of Matthias Evert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
4776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bitzer M, Gross S, Albert J, Blodt S, Boda-Heggemann J, Borucki K, et al.
Z Gastroenterol
. 2025 Mar;
63(3):293-336.
PMID: 40064174
No abstract available.
2.
Bitzer M, Gross S, Albert J, Blodt S, Boda-Heggemann J, Borucki K, et al.
Z Gastroenterol
. 2025 Mar;
63(3):e159-e260.
PMID: 40064172
No abstract available.
3.
Schulz H, Abdelfattah F, Heinrich A, Melnik D, Sandt V, Kruger M, et al.
Biomolecules
. 2025 Feb;
15(2).
PMID: 40001606
Prostate cancer (PC) is the most diagnosed cancer in males across the globe. Following the formation of metastasis, PC is linked to a notable decline in both prognosis and survival...
4.
Liao W, Zhang Y, Wang J, Cui G, Evert M, Xu M, et al.
Hepatology
. 2025 Feb;
PMID: 39999468
Background Aims: Hepatoblastoma (HB) is the predominant primary malignant liver tumor in childhood. Concomitant YAP and β-Catenin activation occurs in most HB. However, the signaling pathways distinctively regulated by YAP...
5.
Gross S, Bitzer M, Albert J, Blodt S, Boda-Heggemann J, Borucki K, et al.
Z Gastroenterol
. 2025 Feb;
63(2):169-203.
PMID: 39919782
No abstract available.
6.
Gross S, Bitzer M, Albert J, Blodt S, Boda-Heggemann J, Borucki K, et al.
Z Gastroenterol
. 2025 Feb;
63(2):e82-e158.
PMID: 39919781
No abstract available.
7.
Zhou Y, Zhang S, Qiu G, Wang X, Yonemura A, Xu H, et al.
J Clin Invest
. 2024 Sep;
134(22).
PMID: 39325536
Activated mTORC2/AKT signaling plays a role in hepatocellular carcinoma (HCC). Research has shown that TSC/mTORC1 and FOXO1 are distinct downstream effectors of AKT signaling in liver regeneration and metabolism. However,...
8.
Lu X, Zhang Y, Xue J, Evert M, Calvisi D, Chen X, et al.
Toxicol Sci
. 2024 Sep;
203(1):41-51.
PMID: 39316419
Mitotic arrest-deficient 2 like 1 (MAD2L1) is a component of the mitotic spindle assembly checkpoint implicated in cancer cell proliferation and tumorigenesis. The functional role of MAD2L1 in hepatocellular carcinoma...
9.
Menzel M, Martis-Thiele M, Goldschmid H, Ott A, Romanovsky E, Siemanowski-Hrach J, et al.
Eur J Cancer
. 2024 Sep;
211:114306.
PMID: 39293347
Introduction: Whole Exome Sequencing (WES) has emerged as an efficient tool in clinical cancer diagnostics to broaden the scope from panel-based diagnostics to screening of all genes and enabling robust...
10.
Cigliano A, Gigante I, Serra M, Vidili G, Simile M, Steinmann S, et al.
J Exp Clin Cancer Res
. 2024 Sep;
43(1):253.
PMID: 39243039
Background: Intrahepatic cholangiocarcinoma (iCCA) is a lethal primary liver tumor characterized by clinical aggressiveness, poor prognosis, and scarce therapeutic possibilities. Therefore, new treatments are urgently needed to render this disease...